PT PYFA Named Best Pharmaceutical CDMO and Global Expansion Leader

The achievement comes amid a rapid shift in the global healthcare industry towards supply-chain efficiency through contract manufacturing partnerships.

Jakarta (ANTARA) — PT Pyridam Farma Tbk has received the Best Pharmaceutical CDMO & Global Expansion Leader award in the Indonesia Best Pharmaceuticals category of the healthcare sector in Jakarta. The award recognises the company’s strategic strengths in integrating good corporate governance, sustainability and digital transformation.

Savira Tjan, PYFA’s Head of CDMO for its Indonesian operations, said the award demonstrated the resilience of the company’s business model, which includes Contract Development and Manufacturing Organization (CDMO) services, pharmaceutical contract manufacturing and cross-border toll manufacturing. These businesses are key drivers of the company’s performance growth.

“As the representative leading the CDMO business line in Indonesia, we are committed to becoming the strategic partner of choice for multinational companies and leading businesses in Indonesia,” Savira said in a statement issued in Jakarta on Sunday.

She said the Best Pharmaceutical CDMO & Global Expansion Leader award from an industry news portal was tangible recognition of PYFA’s strong partnerships with multinational companies and leading businesses in Indonesia.

The achievement, she added, reflects the global healthcare industry’s rapid shift towards more efficient supply chains through contract manufacturing partnerships.

According to a 2026 global market research report by Cervicorn Consulting, the global pharmaceutical CDMO market was valued at more than US$263.04 billion to US$275 billion in 2026. It is projected to reach US$520.27 billion by 2035, with a compound annual growth rate of between 7.06% and 10%. The Asia-Pacific region is the fastest-growing market globally.

Strong demand from global pharmaceutical principals to outsource production through contract manufacturing and toll manufacturing is creating significant expansion opportunities for PYFA, which has prepared internationally standardised manufacturing infrastructure in Indonesia and Australia.

PYFA was named the winner after receiving the highest score from the judging panel across four main criteria: CDMO performance, CDMO innovation, operational efficiency, and commitment to sustainability and global expansion.

The operational achievement is reflected in PYFA’s financial performance, which has attracted attention in the capital market. In its full-year 2025 financial report, PYFA’s revenue rose 43.7% to Rp2.7 trillion from Rp1.9 trillion in FY2024. CDMO services have consistently contributed to revenue growth over the past two reporting periods.

The company said PYFA’s competitive advantage lies in its ability to offer innovative product solutions and extensive services to all its clients.

These capabilities are considered well suited to capturing opportunities amid the pharmaceutical industry’s increasingly dynamic growth, ultimately strengthening the company’s business fundamentals.

“Strong client demand and positive industry growth trends are directly reflected in PYFA’s overall performance. Over the past two years, the CDMO business line has consistently been the main driver of the company’s revenue surge, which grew 43.7% to Rp2.76 trillion, while gross margin remained strong at 21.1%. Going forward, we will continue to raise our service standards and product innovation to deliver the greatest added value to all our business partners and stakeholders,” she said.